Next Article in Journal
Involvement of Glutaredoxin and Thioredoxin Systems in the Nitrogen-Fixing Symbiosis between Legumes and Rhizobia
Next Article in Special Issue
Oxidation of Peroxiredoxin 6 in the Presence of GSH Increases its Phospholipase A2 Activity at Cytoplasmic pH
Previous Article in Journal / Special Issue
Regulation of Oxidative Stress in Corneal Endothelial Cells by Prdx6
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 7
Issue 12
10.3390/antiox7120181
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of Small Peptides that Inhibit NADPH Oxidase (Nox2) Activation

by
Aron B. Fisher
*,
Chandra Dodia
and
Sheldon I. Feinstein
Institute for Environmental Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Antioxidants 2018, 7(12), 181; https://doi.org/10.3390/antiox7120181
Submission received: 26 October 2018 / Revised: 19 November 2018 / Accepted: 20 November 2018 / Published: 5 December 2018
(This article belongs to the Special Issue Peroxiredoxin 6 as a Unique Member of the Peroxiredoxin Family)
Browse Figures
Review Reports Versions Notes

Abstract

:
Nicotinamide adenine phosphate (NADPH) oxidase type 2 (Nox2), a major source of reactive oxygen species in lungs, plays an important role in tissue damage associated with acute inflammatory diseases. The phospholipase A2 (PLA2) activity of peroxiredoxin 6 (Prdx6), called aiPLA2, is required for Nox2 activation through its role in the cellular generation of Rac, a key cytosolic component of the activation cascade. Lung surfactant protein A (SP-A) binds to Prdx6, inhibits its aiPLA2 activity, and prevents activation of Nox2. Based on protein docking software, we previously identified a 16 amino acid (aa) peptide derived from rat SP-A as the Prdx6 binding motif. We now identify the minimal effective sequences of rat/mouse and human SP-A as 9-aa sequences that we have called PLA2-inhibitory peptide (PIP).These sequences are PIP-1, rat/mouse; PIP-2, human; and PIP-3, a hybrid of PIPs 1&2. aiPLA2 activity in vitro was inhibited by 50% with ~7–10 µg PIP/µg Prdx6. Inhibition of the aiPLA2 activity and Nox2 activation of lungs in vivo was similar for intratracheal (IT) and intravenous (IV) administration of PIP-2, but required its incorporation into liposomes as a delivery vehicle; tissue ½ time for decrease of the in vivo inhibition of aiPLA2 activity after PIP-2 administration was ~50 h. These properties suggest that PIP-2 could be an effective therapeutic agent to prevent tissue injury associated with lung inflammation.

Graphical Abstract

1. Introduction

The term ‘reactive oxygen species’, abbreviated as ROS, comprises superoxide anion (O2−•), a free radical, and the non-radical H2O2, along with other chemically reactive compounds derived from the metabolism of molecular O2. ROS are generated normally during cellular metabolism by a variety of enzymatic as well as non-enzymatic pathways. However, the seven-member family of NADPH oxidases (Nox) and related dual oxidases (Duox) are the only enzymes that are known to generate ROS as their primary product [1]. Nox2, the first of the NOX/Duox family of enzymes to be described, is expressed widely in tissues with especially high levels in polymorphonuclear leukocytes (PMN) and macrophages, where it is localized primarily to intracellular phagolysosomes, and in pulmonary and cardiovascular endothelium where it is localized to the plasma membrane [2]. Intracellular Nox2 is inactive in the resting state but can be activated by a complex and tightly controlled pathway [3]. Control of activation is critical since the uncontrolled production of ROS can lead to oxidative damage to tissues.
The activation of the enzymatic activity of Nox2 to produce ROS requires the phosphorylation of several cytosolic proteins (p67phox, p47phox, and p40phox) and the activation of Rac (1 or 2, depending on the cell type) [4,5,6]. Activation of Rac occurs through its dissociation from a complex with Rho protein GDP dissociation inhibitor (Rho-GDI) and formation of Rac-GTP. Activated Rac binds to phosphorylated p67phox, facilitating its translocation (along with other cytosolic Nox2 co-factors) to the plasma membrane where the cytosolic proteins interact with the cell membrane-localized Nox2 complex (consisting of the proteins Nox2 plus p22phox) [4,6,7]; upon activation, the Nox2 protein can transfer an electron from NADPH to molecular O2 to generate O2−•. Dismutation of O2−•, either spontaneously or through the activity of superoxide dismutase, produces H2O2. For some time, these ROS have been known to play an important role in bodily defenses against infection through their bactericidal activity [2,8]. Recent studies have demonstrated that ROS also play an essential role in normal cell biology, providing the molecular signals that regulate cell motility, cell division, programmed cell death, and various other basal biological functions [9,10].
An outstanding question regarding the regulation of Nox2 relates to the upstream signals that initiate the Nox2 activation cascade. Previous studies have indicated that a phospholipase A2 (PLA2) enzyme plays an important role [11,12,13]. PLA2 represents a large family of lipid hydrolases that includes both secreted proteins that function extracellularly and intracellular proteins with specific subcellular localizations [14]. Furthermore, although all PLA2s hydrolyze phospholipids at their sn-2 position, many show some phospholipid substrate specificity. Earlier, the enzyme known as cytosolic PLA2 (cPLA2) was suggested as responsible for Nox2 activation [15], but that was not confirmed by a comprehensive study with cPLA2 null mice [16].
We recently have described the PLA2 activity of peroxiredoxin 6 (Prdx6) and shown that it is specifically involved in activation of Nox2 [7,17]. This PLA2, that we have called aiPLA2 based on its activity at acidic pH, is expressed widely in tissues. [18,19]. Prdx6 is present mainly in cytosol where it has minimal PLA2 activity but phosphorylation (via MAP kinases) results in its translocation to the plasma membrane where it binds to cell membrane phospholipids resulting in a marked increase in PLA2 activity [18]. The enzyme also is present in some organelles with acidic internal content such as lysosomes and lysosomal-related organelles; these organelles express aiPLA2 activity in the non-phosphorylated state, albeit at a considerably lower level than for the phosphorylated protein [18]. Nox2 activation by Prdx6 is prevented by the presence of MJ33, a mimic of the substrate transition state, that inhibits aiPLA2 activity [17,18,20].Activation of Nox2 also is prevented by mutating Prdx6 to a form (D140A-Prdx6) that specifically lacks a crucial member of the catalytic triad necessary for aiPLA2 activity.
Our recent studies have clarified the role of aiPLA2 in the activation of Nox2 [7,17]. Lipid binding of phosphorylated Prdx6 at the cell membrane is primarily to phosphatidylcholine and the PLA2 activity of Prdx6 with this substrate generates lysophosphatidylcholine (LPC) that, in turn, can be converted via lysophospholipase D activity to lysophosphatidic acid (LPA). LPA binds to its cell membrane receptor resulting in the generation of active Rac. The pathway for the role of aiPLA2 in Nox2 activation is shown in Figure 1.
The impetus for our initial investigation of the interaction of Prdx6 with lung surfactant protein A (SP-A) was a publication showing that a serum protein from the Habu snake with homology to lung surfactant protein A (SP-A) inhibited the PLA2 component of its venom, presumably as a way to prevent accidental poisoning [21]. We confirmed that SP-A itself inhibits Habu snake PLA2 activity and showed further that SP-A can bind to Prdx6 and inhibit its aiPLA2 activity [22,23,24]. Prdx6 is present in lung lysosomal-related organelles, i.e., epithelial cell lamellar bodies (LB), the site of lung surfactant storage [25]. Since SP-A also is present in LB, we postulated that the interaction of Prdx6 with SP-A may be an important physiological mechanism to control the remodeling pathway for the synthesis of lung surfactant phospholipids [23]. Following these initial observations, we identified a 16 amino acid (aa) peptide sequence in SP-A that binds to Prdx6 and inhibits its aiPLA2 activity [26]. This peptide was identified with the ZDOCK program [27] by using molecular sequences in the Protein Data Base (PDB) in order to predict the molecular sites for interaction of the two proteins (Prdx6 and SP-A). Molecular modeling of SP-A used the sequence between the hydrophobic neck region and the collagen-like carbohydrate recognition domain (CRD) of rat/mouse SP-A [28]. Binding by the predicted SP-A-derived peptide to the Prdx6 protein was confirmed by isothermal titration calorimetry, circular dichroism measurement, and inhibition of its aiPLA2 activity [26]. The purpose of the present investigation was to determine the minimal amino acid sequence for an SP-A-derived inhibitory peptide and to evaluate the properties of inhibitory peptides as potential therapeutic agents to prevent Nox2 activation in conditions where excess ROS generation can lead to organ injury. This publication is part of a Forum on Peroxiredoxin 6 as a Unique Member of the Peroxiredoxin Family.

2. Methods

Mice (C57Bl/6) were purchased from The Jackson Laboratory and maintained in the University of Pennsylvania Animal Care Facilities. We have described previously the generation of D140A-Prdx6 expressing mice using ‘knock-in’ technology; the lungs of these mice do not express aiPLA2 activity [29]. Subsequently, the neomycin resistance cassette (NRC) and the flippase gene that was introduced to remove the NRC have been removed from the genome of this mouse [19]. All studies using mice were approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC).
Peptides were synthesized by APeptide Co., Ltd. (Shanghai, China) and were supplied with a mass spectroscopic analysis to verify composition; purity as determined by mass spectroscopy was 94% for PIP-1, 89% for PIP-2, and 91% for PIP-3.
For administration to mice, peptides were incorporated into liposomes that were prepared as previously described [30]. Liposome composition was dipalmitoylphosphatidylcholine (DPPC): egg phosphatidylcholine: phosphatidylglycerol: cholesterol in the molar ratio 50:25:10:15. To measure the in vivo effect of the peptides, mice were injected with PIP-2 by either the intratracheal (IT) or the intravenous (IV) route and were sacrificed at intervals; lungs were removed from mice and homogenized for measurement of aiPLA2 activity.
The PLA2 activity of Prdx6 was measured as described previously [30]. The substrate was dipalmitoylphosphatidylcholine (DPPC) with 3H-9,10-palmitate in the sn-2 position of DPPC incorporated into lung surfactant-like liposomes as described above; substrate was incubated with enzyme for 60 min and activity was calculated from the liberation of 3H-palmitate as measured by scintillation counting.
The generation of ROS by the intact isolated perfused lung was determined from the increased fluorescence associated with the oxidation of Amplex red in the presence of horseradish peroxidase as described previously [17]. Aliquots of perfusate taken at intervals with increasing time of perfusion were analyzed with a spectrofluorometer. Angiotensin II (AngII) was added to lung perfusate to stimulate ROS production through its activation of NOX2, primarily in the lung endothelial cells since these cells express the relevant receptor.

3. Results

3.1. Minimal Effective Peptide Sequence

As indicated above, we previously identified a 16 amino acid peptide corresponding to the amino acids at positions 83 to 99 of the carbohydrate-recognition domain (CRD) of rat SP-A; these aa are located at positions 102–118 in the SP-A monomer. The corresponding sequence in the mouse SP-A CRD is identical in aa composition to the rat sequence. This 16-aa peptide inhibits the aiPLA2 activity of human recombinant Prdx6 by ~66% (Table 1), presumably by binding to Prdx6 as demonstrated previously [26]. We then synthesized peptides in which amino acids were deleted from either the N-terminus or the C-terminus of the 16-aa peptide in order to determine a minimum aa sequence that maintained the ability to inhibit aiPLA2 activity. Deletion of the C-terminal amino acid (Leu) abolished the ability of the peptide to inhibit aiPLA2 activity indicating that this aa is required for effectiveness (Table 1). Deletion from the N-terminus to generate 14-, 12-, 10-, or 9-aa peptides had no effect on the inhibitory activity of the peptide but activity was lost with the eight-aa peptide (Table 1). Thus, the minimal effective sequence for inhibition of aiPLA2 activity is a nine amino acid peptide comprising positions 8 through 16 of the original 16-aa peptide; this nine-aa peptide was called PIP-1.
We next identified the 16-aa peptide in human SPA that was analogous to the rat/mouse sequence and showed that it also inhibited the aiPLA2 activity of recombinant human Prdx6 (Table 2). Similarly to the rat/mouse peptide, deletion of seven aa from the N-terminus maintained its ability to inhibit aiPLA2 activity while deletion of the C-terminal aa abolished its inhibitory activity (Table 2). The active nine-aa peptide derived from the human SP-A sequence was called PIP-2.
On comparing the PIP-1 (rat/mouse) and PIP-2 (human) peptides, the first aa and the terminal 4 aa were identical. Thus, only aa 2 to 5 differed between the two peptides. To evaluate the aa requirements at positions 2–5 for activity, we randomly substituted these with the aa that occurred in the effective sequences (PIPs-1 and -2). The nine-aa peptide LYDIRHQIL, representing a hybrid between the human and rat/mouse sequences, was an effective inhibitor of aiPLA2 activity (~70% inhibition, similar to PIP-2); this peptide, was called PIP-3. Of note, PIP-3, unlike PIPs-1 and -2, is not part of a known naturally occurring protein. Substitution of an I for the F at position 4 in the human peptide decreased the ability to inhibit aiPLA2 by about one-half. An additional 4 peptides synthesized with various combinations of the rat and mouse aa located at positions 2–5 of PIP-1 and PIP-2 were ineffective as aiPLA2 inhibitors (not shown). Finally, we synthesized six different peptides based on the PIP-2 sequence with substitutions at position 6 (Q for H), 7 (K,H,or R for Q), and 8 (V or A for I); none of these substituted peptides were effective inhibitors of aiPLA2 activity.

3.2. Species Variability

The differences between the human and rat/mouse sequences led us to examine the protein database and to extract the amino acid sequences of SP-A for various mammalian species, including five non-human primates, and one avian species (chicken) (Table 3). Only the L at position 9 in the peptide was invariant for these 19 species that were found in the database. An L occurred at position 1 in all but one species (guinea pig) and only one specie (chicken) did not have an H at position 6. The aa at positions 2–5 for the various species generally correspond to either the human or rat peptide sequence or to a combination of those amino acids. Species that show similar sequences to the rat/mouse model for aa in positions 2–5 include the cotton rat, cow, sheep, yak, and pig (Table 3). All sequences of non-human primate SP-A were identical to the human sequence as was the sequence for African elephant SP-A, although the latter was located at position 142–150 in the full length protein instead of position 111–119. The sequences from horse and wolf have a single difference (compared to human) for the aa at position 4. The consensus amino acids for each of the 9 positions were: (1) L,F; (2) H,Y,L; (3) D,E,L,N; (4) F,I,L,N; (5) R,K; (6) H,Q; (7) Q,K,H,R; (8) I,V,A; (9) L, where the amino acids in italics indicate an amino acid present in only a single species. The greatest differences from the human and rat/mouse sequences were seen for the guinea pig, rabbit, and chicken peptides.
Of note, the nine-aa peptide sequence of the wolf protein did not inhibit aiPLA2 activity while the sequence from the horse protein was only ~50% effective. These findings indicate that not all naturally occurring sequences are effective inhibitors (at least, of the human protein) and, if so, suggest that the inhibition of aiPLA2 by SP-A may not represent an important physiologic mechanism for regulating activity of this enzyme.

3.3. Physical Properties of Inhibitory Peptides

The aa sequences and some characteristics of the three inhibitory peptides, PIP-1, PIP-2, and PIP- 3, are shown in Table 4. These peptides have a molecular mass of 1156–1178 with a predicted isoelectric point in the slightly basic range. Each of the three peptides contains four hydrophobic amino acid residues, with two of those on the same surface, and one negatively charged hydrophilic aa. The PIP-2 sequence has three while PIPs-1 and -3 have only two positively charged aa. PIP-1 is slightly more hydrophobic than the other two peptides but, in our experience, all three peptides readily dissolve in aqueous solution. The protein binding potential (Boman index) was slightly greater for the more hydrophilic PIP-2 indicating that it may bind slightly better to proteins as compared to PIPs-1 and -3. The UV extinction coefficient of PIPs 1 and 3 reflects the presence of a Tyr residue while PIP-2 does not contain an aa that absorbs UV light. No antigenic determinants were identified in these peptides as determined by the free on-line program provided by the Immunomedicine Group of the Universidad Complutense (Madrid, Spain). The chemical stability of PIP-2 was tested by placing the dry powder on the laboratory shelf at room temperature; its inhibition of the aiPLA2 activity of recombinant human Prdx6 was unchanged when measured after nine months of shelf storage indicating good stability of the peptide as a dry powder (data not shown); stability of the other peptides was not tested.

3.5. Inhibition of aiPLA2 Activity In Vitro

The effect of the PIP peptides on the aiPLA2 activity of human recombinant Prdx6 was determined by in vitro assay; the effective concentration of inhibitor was corrected for purity of the PIP preparation. Saturating concentrations of all three peptides (PIP-1, PIP-2, PIP-3) inhibited aiPLA2 activity by ~70% (Figure 2). The basis for the remaining 30% of activity that was not inhibited is unclear. The concentration of peptide (µg/mg Prdx6) for inhibition of aiPLA2 activity by 50% was ~8.3 for PIP-1, ~6.6 for PIP-2, and ~10 for PIP-3 indicating slightly greater effectiveness of PIP-2 as an inhibitor. The ratio of the molecular mass of the nine-aa peptides to Prdx6 (monomeric MW~25 kDa) is ~0.047 while maximal inhibition of activity was seen at a ratio of PIP to Prdx6 concentration of ~0.030 (Figure 2); this indicates a stoichiometry of approximately 1.5 to 1 for molar binding of the peptide to the Prdx6 monomer at maximal inhibition of activity.
As determined by protein truncation and ITC, the site on Prdx6 for binding of the 16-aa peptide derived from rat/mouse protein was in the Prdx6 C-terminus (aa 210–225). This sequence does not include the aiPLA2 active site (S32-D140-H26) [33]. Thus, unlike MJ33 that competitively inhibits aiPLA2 activity as an analogue of the substrate transition state [34], inhibition of aiPLA2 activity by the SP-A derived peptide is non-competitive. The mechanism for inhibition of aiPLA2 activity through binding of the peptide to the enzyme is an alteration of the secondary structure of the protein, as shown by far UV circular dichroism [21].

3.6. Intracellular Delivery of PIP-2

Most small peptides are unable to cross cell membranes and thus their activity toward intracellular targets requires either aa modification or the use of a ‘delivery vehicle’. In order to evaluate the permeability of lung cells to PIP-2, we perfused isolated lungs for 15 min with the peptide alone or with the peptide encapsulated in liposomes; the perfusing medium was then switched to PIP-2 free (to remove any PIP-2 containing extracellular medium), and then Ang II was added to activate endothelial Nox2. Finally, Amplex red (plus horseradish peroxidase) was added to the recirculating perfusate in order to measure ROS production. Lung perfusion and ROS production were determined similarly at 15 min after intratracheal instillation of PIP-2, with or without liposomes. Our previous studies in rats and mice have shown that intratracheal instillation of these liposomes results in their rapid distribution throughout the lung and their rapid uptake by lung cells [35]. The linear rate of increase of oxidized Amplex red in the perfusate of control lungs (no PIP) indicates a continuous rate of Ang II-stimulated H2O2 production during the 1 h perfusion period (Figure 3). Perfusion with PIP-2 dispersed in saline (no liposomes) essentially had minimal effect on lung ROS production. Treatment of lungs with PIP-2 in liposomes, administered either by the IV or the IT route, led to a marked decrease in the rate of ROS production, compatible with the inhibition of lung aiPLA2 activity so that lung NOX2 was not activated by Ang II. PIP-2 incorporated into surfactant-like liposomes prior to lung perfusion resulted in ~75% inhibition of ROS production and results were similar for administration by either the IV or IT route (Figure 3). A similar experiment (not shown) with Nox2 null lungs showed a rate of Amplex red oxidation similar to the PIP-2 inhibited rate, indicating a low level of Amplex red oxidation by non-Nox2 dependent sources of ROS.
To confirm the requirement for liposomes as a delivery vehicle, lungs were perfused for 15 min with PIP-2 incorporated or not into liposomes, then perfused with fresh medium to clear extracellular PIP-2, and then homogenized and assayed for aiPLA2 activity. PIP-2 administered without liposomes had no effect on aiPLA2 activity of the lung homogenate while PIP-2 in liposomes inhibited activity by ~80% (Table 5).

3.7. Effect of PIP-2 on aiPLA2 Activity In Vivo and its Biological Stability

To determine the effect and duration of a single dose of PIP-2 on aiPLA2 activity of mouse lungs in vivo, mice were injected with PIP-2 in liposomes by either the intratracheal (IT) or the intravenous (IV) route; individual lungs were removed at intervals, homogenized, and assayed for aiPLA2 activity. Lung aiPLA2 activity was inhibited by slightly greater than 80% after PIP-2 injection by either the IV or IT route (Figure 4). PLA2 activity in lungs remained depressed for 24 h, had begun recovery by 36 h, and was recovered fully by 72 h. The half-time for recovery was estimated at ~50 h.

3.8. Specificity of PLA2 Inhibition

Lung cells, like those of other organs, have multiple PLA2 enzymes [14]. We evaluated the specificity of PIP-2 for inhibition of Prdx6 by measuring aiPLA2 activity in the lung homogenate of wild type and D140A-Prdx6 mutant mice. Lungs from the mutant mice do not express aiPLA2 activity since D140 is a key component of the aiPLA2 catalytic triad [29,33]. Measurement of PLA2 activity at pH 4 in the absence of Ca2+ is relatively specific for the PLA2 activity of Prdx6 (aiPLA2) [18]. This activity was inhibited by 91% following addition of PIP-2 to the assay of the lung homogenate (Table 6). Although Prdx6 has relatively little PLA2 activity when measured at pH 7, other lung PLA2 enzymes, some of which are Ca2+-dependent for activity, show activity at neutral pH; this activity was not affected by mutation of D140 in Prdx6 (Table 6). Unlike the effect of PIP-2 on aiPLA2 activity at pH 4, the addition of PIP-2 had no effect on activity of the lung PLA2 enzymes that are active at pH 7. Thus, aiPLA2 appears to be the only PLA2 enzyme, at least in the lung, that is inhibited by PIP-2. That result is not surprising since the specificity of binding of PIP-2 to the Prdx6 protein is the basis for its inhibition of aiPLA2 activity and other PLA2 enzymes do not share aa sequence homology with Prdx6.

4. Discussion

The goal of the present investigation was to follow up on our published observation that a 16-aa peptide derived from the rat SP-A sequence could bind to Prdx6 and inhibit its aiPLA2 activity [26]. We first verified, through search of the Protein Data Base (PDB), that the rat and mouse sequences in the relevant part of the SP-A carbohydrate recognition domain (CRD), were identical. We next verified the corresponding region in the human SP-A CRD and confirmed that this peptide also inhibited aiPLA2 activity, similar to the rat/mouse peptide. We found that progressive deletion of seven aa from the N-terminus of either the rat/mouse or the human 16aa sequences had no effect on the inhibitory activity of the peptides, while activity was lost with deletion of eight aa from the N-terminus or deletion of the C-terminal aa. Thus, a nine-aa peptide represents the minimal sequence that was effective as an aiPLA2 inhibitory peptide.
Examination of the sequences of the two peptides (human and rat/mouse) showed identical aa in position 1 and positions 6–9 (LxxxxQHIL), while peptides 2–5 varied. We have named these PLA2-inhibitory peptides as PIP-1 (rat/mouse) and PIP-2 (human). Substitution of aa 2 and 4 from the rat/mouse sequence into the corresponding positions of the human sequence resulted in a hybrid peptide (called PIP-3) that also had aiPLA2 inhibitory activity. However, a hybrid peptide with the aa from positions 3 and 5 of the rat/mouse sequence inserted into the human sequence was not active while insertion of an I for F at position 4 of the human sequence decreased activity by ~50%. Thus, only some aa in positions 2–5 supported activity of the peptide. Furthermore, a review of the natural sequences from a variety of species in the PDB indicated that, while the human sequence was well represented and found intact in non-human primates and the African elephant, other species showed variable aa in eight of the nine positions and only the terminal leucine was present in all. Thus, it is not possible to accurately predict the peptide sequences that will be effective as inhibitors of aiPLA2 activity and further testing of individual constructs will be necessary in order to fully grasp the role of individual aa and their combination for aiPLA2 inhibition. Since there is only modest conservation of the inhibitory sequence in various species while at least one corresponding naturally occurring sequence (in wolf SP-A) does not inhibit aiPLA2 activity, we conclude that SP-A modulation of aiPLA2 activity is unlikely to represent an important physiological function.
PIP-2 was selected as the prototype peptide for further testing. This peptide effectively inhibited the aiPLA2 activity of recombinant Prdx6 in vitro. Calculation of the concentration of peptide required for maximal inhibition of activity indicated binding that was approximately to 1.5:1 of inhibitor to enzyme on a molar basis. PIP-2, administered to mice by either the IT or IV route, also inhibited the endogenous aiPLA2 activity in the homogenized lung; the inhibition by either route of administration was similar. Like many peptides [36], PIP-2 was not able to cross the cell membrane and its effectiveness as an inhibitor required its administration with a liposomal carrier. Surprisingly, the peptide within the lung cells appeared to be relatively stable, and inhibition of aiPLA2 activity was demonstrated with a half-time of ~50 h after peptide administration. Testing of lungs with genetic absence of aiPLA2 (D140A-Prdx6 mutation) or under assay conditions that do not support aiPLA2 activity (pH 7) provide evidence that aiPLA2 is the only lung PLA2 enzyme that is inhibited by the PIP-2 peptide.
The ability of PIP-2 to inhibit the activation of Nox2 in response to angiotensin II was demonstrated with the isolated perfused lung preparation using Amplex red in the perfusate as a trap for the generated ROS. This result was expected based on our previous studies demonstrating that aiPLA2 activity in lungs is required for activation of Nox2 [7,17], although Prdx6 also may be involved in the activation of Nox1 [37]. At any rate, our previous studies have shown that nearly all ROS production in response to angiotensin II is abolished with ‘knock-out’ of Nox2 and that the addition of an aiPLA2 inhibitor to Nox2 null lungs has little additional effect [7,17,20]. Thus, the effect of PIP-2 in angiotensin II-treated lungs appears to be predominantly due to the inhibition of Nox2 activation with essentially no contribution due to inhibition of Nox1.

5. Conclusions

The present studies indicate that the PIP peptides can effectively prevent ROS generation by the intact mouse lung. Based on results with mouse lungs, both the inhibitory dose of PIP-2 as well as its persistence within lung cells are in a reasonable range for potential therapeutic application to treat conditions with excess ROS generation subsequent to Nox2 activation. One potential therapeutic use of the PIP peptides might be to prevent inflammation-mediated tissue injury such as occurs with the Acute Lung Injury syndrome [21]. As PIP-2 is derived from a normal lung protein, it is expected to be relatively non-toxic by itself, although its possible antigenicity as well as the long term effects of the inhibition of aiPLA2 activity will require further evaluation.

Author Contributions

Formulated research plan (A.B.F., S.I.F.); generated recombinant Prdx6 (S.I.F.); performed experiments (C.D.); interpreted experimental results (A.B.F., S.I.F.); wrote the manuscript (A.B.F.).

Funding

This research was supported in part by grant R01-HL102016 (P.I, A.B.F.) from the National Institutes of Health of the United States.

Acknowledgements

We thank Shampa Chatterjee for helpful discussion and Dawn Williams for assistance with manuscript preparation.

Conflicts of Interest

S.I.F. and A.B.F. have a patent application pending for peptide inhibitors of peroxiredoxin 6 PLA2 activity and have part ownership of a start-up company to promote their clinical use.

References

  1. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007, 87, 245–313. [Google Scholar] [CrossRef] [PubMed]
  2. Babior, B.M. NADPH oxidase: An update. Blood 1999, 93, 1464–1476. [Google Scholar] [PubMed]
  3. Diebold, B.A.; Smith, S.M.; Li, Y.; Lambeth, J.D. NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress. Antioxid. Redox Signal. 2015, 23, 375–405. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Pick, E.; Gorzalczany, Y.; Engel, S. Role of the rac1 p21-GDP-dissociation inhibitor for rho heterodimer in the activation of the superoxide-forming NADPH oxidase of macrophages. Eur. J. Biochem. 1993, 217, 441–455. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Pick, E. Cell-free NADPH oxidase activation assays: "In vitro veritas". Methods Mol. Biol. 2014, 1124, 339–403. [Google Scholar] [CrossRef] [PubMed]
  6. Brandes, R.P.; Weissmann, N.; Schroder, K. Nox family NADPH oxidases: Molecular mechanisms of activation. Free Radic. Biol. Med. 2014, 76, 208–226. [Google Scholar] [CrossRef] [PubMed]
  7. Vazquez-Medina, J.P.; Dodia, C.; Weng, L.; Mesaros, C.; Blair, I.; Feinstein, S.I.; Chatterjee, C.; Fisher, A. The phospholipase A2 activity of peroxiredoxin 6 modulates NADPH oxidase 2 activation via lysophosphatidic acid receptor signaling in the pulmonary endothelium and alveolar macrophages. FASEB J. 2016, 30, 2885–2898. [Google Scholar] [CrossRef]
  8. Nauseef, W.M. Biological roles for the NOX family NADPH oxidases. J. Biol. Chem. 2008, 283, 16961–16965. [Google Scholar] [CrossRef]
  9. Bernard, K.; Hecker, L.; Luckhardt, T.R.; Cheng, G.; Thannickal, V.J. NADPH oxidases in lung health and disease. Antioxid. Redox Signal. 2014, 20, 2838–2853. [Google Scholar] [CrossRef]
  10. Moloney, J.N.; Cotter, T.G. ROS signalling in the biology of cancer. Semin. Cell Dev. Biol. 2018, 80, 50–64. [Google Scholar] [CrossRef]
  11. Bromberg, Y.; Pick, E. Unsaturated fatty acids as second messengers of superoxide generation by macrophages. Cell Immunol. 1983, 79, 240–252. [Google Scholar] [CrossRef]
  12. Henderson, L.M.; Chappell, J.B.; Jones, O.T. Superoxide generation is inhibited by phospholipase A2 inhibitors. Role for phospholipase A2 in the activation of the NADPH oxidase. Biochem. J. 1989, 264, 249–255. [Google Scholar] [CrossRef] [PubMed]
  13. Dana, R.; Malech, H.L.; Levy, R. The requirement for phospholipase A2 for activation of the assembled NADPH oxidase in human neutrophils. Biochem. J. 1994, 297, 217–223. [Google Scholar] [CrossRef] [PubMed]
  14. Burke, J.E.; Dennis, E.A. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, 50, S237–S242. [Google Scholar] [CrossRef] [PubMed]
  15. Dana, R.; Leto, T.L.; Malech, H.L.; Levy, R. Essential requirement of cytosolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J. Biol. Chem. 1998, 273, 441–445. [Google Scholar] [CrossRef]
  16. Rubin, B.B.; Downey, G.P.; Koh, A.; Degousee, N.; Ghomashchi, F.; Nallan, L.; Stefanski, E.; Harkin, D.W.; Sun, C.; Smart, B.P.; et al. Cytosolic phospholipase A2-alpha is necessary for platelet-activating factor biosynthesis, efficient neutrophil-mediated bacterial killing, and the innate immune response to pulmonary infection: cPLA2-alpha does not regulate neutrophil NADPH oxidase activity. J. Biol. Chem. 2005, 280, 7519–7529. [Google Scholar] [CrossRef]
  17. Chatterjee, S.; Feinstein, S.I.; Dodia, C.; Sorokina, E.; Lien, Y.C.; Nguyen, S.; Debolt, K.; Speicher, D.; Fisher, A.B. Peroxiredoxin 6 phosphorylation and subsequent phospholipase A2 activity are required for agonist-mediated activation of NADPH oxidase in mouse pulmonary microvascular endothelium and alveolar macrophages. J. Biol. Chem. 2011, 286, 11696–11706. [Google Scholar] [CrossRef]
  18. Fisher, A.B. The Phospholipase A2 Activity of Peroxiredoxin 6. J. Lipid Res. 2018, 59, 1132–1147. [Google Scholar] [CrossRef]
  19. Vazquez-Medina, J.P.; Tao, J.Q.; Patel, P.; Bannitz-Fernandes, R.; Dodia, C.; Sorokina, E.M.; Feinstein, S.I.; Chatterjee, S.; Fisher, A.B. Genetic inactivation of the phospholipase A2 activity of peroxiredoxin 6 in mice protects against LPS-induced acute lung injury. Am. J. Physiol. Lung 2018. under review. [Google Scholar]
  20. Lee, I.; Dodia, C.; Chatterjee, S.; Zagorski, J.; Mesaros, C.; Blair, I.A.; Feinstein, S.I.; Jain, M.; Fisher, A.B. A novel nontoxic inhibitor of the activation of NADPH oxidase reduces reactive oxygen species production in mouse lung. J. Pharmacol. Exp. Ther. 2013, 345, 284–296. [Google Scholar] [CrossRef]
  21. Lee, I.; Dodia, C.; Chatterjee, S.; Feinstein, S.I.; Fisher, A.B. Protection against LPS-induced acute lung injury by a mechanism based inhibitor of NADPH-oxidase (Type 2). Am. J. Physiol. Lung Cell Mol. Physiol. 2014, 306, 635–644. [Google Scholar] [CrossRef] [PubMed]
  22. Fisher, A.B.; Dodia, C.; Chander, A.; Beers, M.F.; Bates, S.R. Inhibition of Trimeresurus flavoviridis phospholipase A2 by lung surfactant protein A (SP-A). Biochim. Biophys. Acta 1994, 1211, 256–262. [Google Scholar] [CrossRef]
  23. Wu, Y.Z.; Manevich, Y.; Baldwin, J.L.; Dodia, C.; Yu, K.; Feinstein, S.I.; Fisher, A.B. Interaction of surfactant protein A with peroxiredoxin 6 regulates phospholipase A2 activity. J. Biol. Chem. 2006, 281, 7515–7525. [Google Scholar] [CrossRef] [PubMed]
  24. Fisher, A.B.; Dodia, C.; Chander, A. Inhibition of lung calcium-independent phospholipase A2 by surfactant protein A. Am. J. Physiol. Lung Cell Mol. Physiol. 1994, 267, L335–L341. [Google Scholar] [CrossRef] [PubMed]
  25. Sorokina, E.M.; Feinstein, S.I.; Zhou, S.; Fisher, A.B. Intracellular targeting of peroxiredoxin 6 to lysosomal organelles requires MAPK activity and binding to 14-3-3epsilon. Am. J. Physiol. Lung Cell Mol. Physiol. 2011, 300, C1430–C1441. [Google Scholar] [CrossRef] [PubMed]
  26. Krishnaiah, S.; Dodia, C.; Sorokina, E.; Feinstein, S.I.; Fisher, A. Binding sites for interaction of peroxiredoxin 6 with surfactatn protein A. BBA Proteins Proteom. 2015, 1864, 419–425. [Google Scholar] [CrossRef] [PubMed]
  27. Protein Docking and Design program. Available online: https://zlab.bu.edu/zlab/index.shtml (accessed on 26 October 2018).
  28. Head, J.F.; Mealy, T.R.; McCormack, F.X.; Seaton, B.A. Crystal structure of trimeric carbohydrate recognition and neck domains of surfactant protein A. J. Biol. Chem. 2003, 278, 43254–43260. [Google Scholar] [CrossRef]
  29. Li, H.; Benipal, B.; Zhou, S.; Dodia, C.; Chatterjee, S.; Tao, J.Q.; Sorokina, E.M.; Raabe, T.; Feinstein, S.I.; Fisher, A.B. Critical role of peroxiredoxin 6 in the repair of peroxidized cell membranes following oxidative stress. Free Radic. Biol. Med. 2015, 87, 356–365. [Google Scholar] [CrossRef] [Green Version]
  30. Fisher, A.B.; Dodia, C.; Feinstein, S.I.; Ho, Y.S. Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. J. Lipid Res. 2005, 46, 1248–1256. [Google Scholar] [CrossRef] [Green Version]
  31. Tools for Antimicrobial Peptides. Available online: aps.unmc.edu/AP/tools.php (accessed on 26 October 2018).
  32. Predicted Antigenic Peptides. Available online: http://imed.med.ucm.es/Tools/antigenic.pl (accessed on 26 October 2018).
  33. Manevich, Y.; Reddy, K.S.; Shuvaeva, T.; Feinstein, S.I.; Fisher, A.B. Structure and phospholipase function of peroxiredoxin 6: Identification of the catalytic triad and its role in phospholipid substrate binding. J. Lipid Res. 2007, 48, 2306–2318. [Google Scholar] [CrossRef]
  34. Jain, M.K.; Tao, W.J.; Rogers, J.; Arenson, C.; Eibl, H.; Yu, B.Z. Active-site-directed specific competitive inhibitors of phospholipase A2: Novel transition-state analogues. Biochemistry 1991, 30, 10256–10268. [Google Scholar] [CrossRef] [PubMed]
  35. Fisher, A.B.; Dodia, C.; Chander, A. Beta-adrenergic mediators increase pulmonary retention of instilled phospholipids. J. Appll. Physiol. 1985, 59, 743–748. [Google Scholar] [CrossRef] [PubMed]
  36. Yang, N.J.; Hinner, M.J. Getting across the cell membrane: An overview for small molecules, peptides, and proteins. Methods Mol. Biol. 2015, 1266, 29–53. [Google Scholar] [CrossRef] [PubMed]
  37. Kwon, J.; Wang, A.; Burke, D.J.; Boudreau, H.E.; Lekstrom, K.J.; Korzeniowska, A.; Sugamata, R.; Kim, Y.S.; Yi, L.; Ersoy, I.; et al. Peroxiredoxin 6 (Prdx6) supports NADPH oxidase1 (Nox1)-based superoxide generation and cell migration. Free Radic. Biol. Med. 2016, 96, 99–115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Antioxidants 07 00181 g001 550
Figure 1. The pathway for activation of NADPH oxidase type 2 (Nox2). This pathway requires generation of lysophosphatidylcholine (LPC) through the PLA2 activity of phosphorylated Prdx6; LPC is converted to lysophosphatidic acid (LPA) that binds to its cell membrane-localized receptor (LPAR1) leading to the activation of Rac (1 or 2). Activated Rac (Rac-GTP) binds to p67phox and it along with other phosphorylated cytoplasmic factors (shown in green) bind to the membrane-localized Nox2 complex resulting in its activation to generate reactive oxygen species (ROS). The presence of one of the PLA2-inhibitory proteins (PIP-1, -2, or -3) inhibits PLA2 activity and prevents Nox2 activation. PC, phosphatidylcholine; LysoPLD, lysophospholipase D; MAP kinase, mitogen activated protein kinase. Modified from [7] and reprinted with permission.
Figure 1. The pathway for activation of NADPH oxidase type 2 (Nox2). This pathway requires generation of lysophosphatidylcholine (LPC) through the PLA2 activity of phosphorylated Prdx6; LPC is converted to lysophosphatidic acid (LPA) that binds to its cell membrane-localized receptor (LPAR1) leading to the activation of Rac (1 or 2). Activated Rac (Rac-GTP) binds to p67phox and it along with other phosphorylated cytoplasmic factors (shown in green) bind to the membrane-localized Nox2 complex resulting in its activation to generate reactive oxygen species (ROS). The presence of one of the PLA2-inhibitory proteins (PIP-1, -2, or -3) inhibits PLA2 activity and prevents Nox2 activation. PC, phosphatidylcholine; LysoPLD, lysophospholipase D; MAP kinase, mitogen activated protein kinase. Modified from [7] and reprinted with permission.
Antioxidants 07 00181 g001
Antioxidants 07 00181 g002 550
Figure 2. Effect of the concentration of PIP peptides on the aiPLA2 activity of recombinant human Prdx6. Results are mean + SEM for n = 3.
Figure 2. Effect of the concentration of PIP peptides on the aiPLA2 activity of recombinant human Prdx6. Results are mean + SEM for n = 3.
Antioxidants 07 00181 g002
Antioxidants 07 00181 g003 550
Figure 3. PIP-2 if encapsulated in liposomes inhibits lung ROS production when administered to. mice by either intratracheal (IT) or intravenous (IV) injection. PIP-2, with or without liposomes, and angiotensin II (to stimulate ROS production via NOX2) were administered to intact mice. Lungs were isolated 30 min later and ROS production was measured in the perfused lung by the oxidation of Amplex red plus horseradish peroxidase that were added to the lung perfusate.
Figure 3. PIP-2 if encapsulated in liposomes inhibits lung ROS production when administered to. mice by either intratracheal (IT) or intravenous (IV) injection. PIP-2, with or without liposomes, and angiotensin II (to stimulate ROS production via NOX2) were administered to intact mice. Lungs were isolated 30 min later and ROS production was measured in the perfused lung by the oxidation of Amplex red plus horseradish peroxidase that were added to the lung perfusate.
Antioxidants 07 00181 g003
Antioxidants 07 00181 g004 550
Figure 4. Persistence and stability of PIP-2 in vivo. PIP-2 was administered to mice either intratracheally (IT) or intravenously (IV) at 0 time. Lungs were harvested at intervals between 4 and 72 h after the PIP-2 administration, homogenized, and analyzed for aiPLA2 activity. Results are mean + SEM for n = 3–4.
Figure 4. Persistence and stability of PIP-2 in vivo. PIP-2 was administered to mice either intratracheally (IT) or intravenously (IV) at 0 time. Lungs were harvested at intervals between 4 and 72 h after the PIP-2 administration, homogenized, and analyzed for aiPLA2 activity. Results are mean + SEM for n = 3–4.
Antioxidants 07 00181 g004
Table
Table 1. Deletion of N- or C-terminal amino acids from 16-aa rat-derived SP-A peptide: effect on the inhibition of the aiPLA2 activity of recombinant hPrdx6.
Table 1. Deletion of N- or C-terminal amino acids from 16-aa rat-derived SP-A peptide: effect on the inhibition of the aiPLA2 activity of recombinant hPrdx6.
Peptide LengthSequence
Delete from N-term		Activity, nmol/min/mg Prot.Sequence
Delete from C-term		Activity, nmol/min/mg Prot.
controlNo peptide94.8Scrambled peptide:
LELDEEITEYQKQLHI		93.5
16 aaDEELQTELYEIKHQIL32.0DEELQTELYEIKHQIL32.0
14 aaELQTELYEIKHQIL33.2DEELQTELYEIKHQ102
12 aaQTELYEIKHQIL31.5No entry
10 aaELYEIKHQIL28.6No entry
9 aaLYEIKHQIL
(PIP-1)		32.3ELYEIKHQI89.6
8 aaYEIKHQIL94.4DEELQTEL93.6
Sequential deletions from the N-terminus or C-terminus of the rat/mouse 16-aa inhibitory peptide were used to determine the minimal effective sequence to inhibit the aiPLA2 activity of peroxiredoxin 6 (Prdx6). The results represent one assay done in duplicate.
Table
Table 2. Deletion of amino acids from the N- or C-terminus of the 16-aa human-derived SP-A peptide: effect on the inhibition of aiPLA2 activity of recombinant hPrdx6.
Table 2. Deletion of amino acids from the N- or C-terminus of the 16-aa human-derived SP-A peptide: effect on the inhibition of aiPLA2 activity of recombinant hPrdx6.
Peptide, Number of Amino AcidsSequenceActivity,
nmol/min/mg Prot.		Comment
No peptideControl92.0No added peptide
16 aaDEELQATLHDFRHQIL45.016 aa human peptide
10 aaTLHDFRHQIL31.5Delete from N-term
9 aaLHDFRHQIL
(PIP-2)		29.9Delete from N-term
9 aaTLHDFRHQI89.6Delete from C-term
Same experiment as in Table 1 but deletions were from the human-derived 16-aa inhibitory peptide. The results represent one assay done in duplicate.
Table
Table 3. Amino acids at the 9 amino acid positions in SP-A between 111-119 for various mammalian and 1 avian species.
Table 3. Amino acids at the 9 amino acid positions in SP-A between 111-119 for various mammalian and 1 avian species.
Species123456789
Human *LHDFRHQIL
Primates †LHDFRHQIL
Elephant (African) #LHDFRHQIL
HorseLHDIRHQIL
WolfLHDLRHQIL
RabbitLHELRHHAL
ChickenLLNLRQRIL
RatLYEIKHQIL
MouseLYEIKHQIL
Cotton ratLHEIKHKIL
CowLHEIRHQVL
YakLHEIRHQVL
SheepLHEIRHQVL
PigLHEIRHQIL
Guinea pigFHLNKHKIL
* Human surfactant protein A1. † gorilla, orangutan, baboon, chimpanzee, rhesus monkey; # peptide is found at aa142–150. Red letters indicate those aa that are not present in the respective positions in either the human or the rat sequence.
Table
Table 4. Properties of inhibitory peptides.
Table 4. Properties of inhibitory peptides.
PropertiesRat/Mouse (PIP-1)Human (PIP-2)Hybrid (PIP-3)
Number of residues999
SequenceLYEIKHQILLHDFRHQILLYDIRHQIL
Molecular weight, g/mol115611781170
Hydrophobic residues
On same surface
Grand average hydropathy		L,I,I,L
I,I
0.1333		L,F,I,L
F,I
−0.3333		L,I,I,L
I,I
0.0666
Charged amino acids: neg pos
Iso-electric point, pH		E
K,H
7.7		D
R,H,H
8.0		D
R,H
7.8
Protein-binding potential, kcal/mol0.332.31.58
Extinction coeff. at 280 nm, M−1cm−1149001490
Antigenic propensity, average1.0771.0571.072
Antigenic determinantsnonenonenone
Calculations and estimations were made by Innovagen’s peptide calculator [27] and the Antimicrobial Peptide Database (APD) predictor [31]; antigenic determinants were evaluated by a program from the immunomedicine group of the Universidad Complutense Madrid, Spain [32].
Table
Table 5. Liposomes are required for inhibition of aiPLA2 activity by PIP-2 in isolated mouse lungs.
Table 5. Liposomes are required for inhibition of aiPLA2 activity by PIP-2 in isolated mouse lungs.
ConditionsaiPLA2 activity nmol/min/mg Prot.
No PIP8.72 ± 0.16
PIP-2 in saline8.50 ± 0.26
PIP-2 in liposomes1.55 ± 0.11
Lungs were perfused with PIP-2 added directly to the perfusate or encapsulated in liposomes prior to addition. After 15 min, lungs were cleared of perfusate, homogenized and aiPLA2 activity was measured. Results are mean ± range for n = 2.
Table
Table 6. PIP-2 specificity as an inhibitor of aiPLA2 as shown by the lack of effect on other PLA2 enzymes.
Table 6. PIP-2 specificity as an inhibitor of aiPLA2 as shown by the lack of effect on other PLA2 enzymes.
Conditions PLA2 activity, nmol/min/mg Prot.
pH 4pH 7 + Ca2+
WTD140A-Prdx6WTD140A-Prdx6
No inhibitor8.7 ± 0.160.2 ± 0.038.5 ± 0.268.3 ± 0.26
+PIP-21.6 ± 0.100.2 ± 0.068.5 + 0.308.5 ± 0.10
Lungs from wild type (WT) and D140A-Prdx6 ‘knock-in’ mice were cleared of blood and homogenized; PLA2 activity of the lung homogenate was measured at pH 4 in the absence of Ca2+ and at pH 7 in the presence of Ca2+. D140A-Prdx6 does not express aiPLA2 activity. Results are mean ± range for n = 2.

Share and Cite

MDPI and ACS Style

Fisher, A.B.; Dodia, C.; Feinstein, S.I. Identification of Small Peptides that Inhibit NADPH Oxidase (Nox2) Activation. Antioxidants 2018, 7, 181. https://doi.org/10.3390/antiox7120181

AMA Style

Fisher AB, Dodia C, Feinstein SI. Identification of Small Peptides that Inhibit NADPH Oxidase (Nox2) Activation. Antioxidants. 2018; 7(12):181. https://doi.org/10.3390/antiox7120181

Chicago/Turabian Style

Fisher, Aron B., Chandra Dodia, and Sheldon I. Feinstein. 2018. "Identification of Small Peptides that Inhibit NADPH Oxidase (Nox2) Activation" Antioxidants 7, no. 12: 181. https://doi.org/10.3390/antiox7120181

APA Style

Fisher, A. B., Dodia, C., & Feinstein, S. I. (2018). Identification of Small Peptides that Inhibit NADPH Oxidase (Nox2) Activation. Antioxidants, 7(12), 181. https://doi.org/10.3390/antiox7120181

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop